Perrigo Company (PRGO) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
20 Mar, 2026Executive summary
The 2026 Annual General Meeting will be held on April 30, 2026, in Dublin, Ireland, with shareholders voting on key proposals including director elections, auditor ratification, executive compensation, a new long-term incentive plan, and renewal of board authorities under Irish law.
The company advanced its '3-S' plan (Stabilize, Streamline, Strengthen), achieving market share gains, innovation pipeline growth, and significant cost savings through Project Energize and Supply Chain Reinvention.
Financial highlights for 2025 include $4.3B in net sales, $622M adjusted operating income, 14.6% adjusted operating margin, $2.75 adjusted EPS, and $239M operating cash flow.
Voting matters and shareholder proposals
Shareholders will vote on electing nine directors, ratifying Ernst & Young LLP as auditor, approving executive compensation, adopting the 2026 Long-Term Incentive Plan, and renewing board authorities to issue shares and opt out of pre-emption rights under Irish law.
All proposals are recommended for approval by the board.
Board of directors and corporate governance
Eight of nine director nominees are independent; the board is refreshed regularly, with four new non-employee directors in the last five years.
The board has separate independent Chair and CEO roles, robust share ownership guidelines, and annual self-assessments.
Committees (Audit, Talent & Compensation, Nominating & Governance) are composed entirely of independent directors.
Directors bring diverse skills in leadership, finance, industry, international business, and ESG.
Latest events from Perrigo Company
- Key votes include director elections, auditor ratification, and executive compensation approval.PRGO
Proxy filing20 Mar 2026 - Gained OTC market share, drove cost savings, and targets growth through innovation and efficiency.PRGO
UBS Global Consumer and Retail Conference11 Mar 2026 - Adjusted EPS up 7% to $2.75; FY2026 outlook cautious amid cost actions and market headwinds.PRGO
Q4 202526 Feb 2026 - Q3 2024 delivered margin expansion, higher adjusted EPS, and infant formula market share gains.PRGO
Q3 20243 Feb 2026 - Adjusted EPS met expectations as margin gains offset sales declines; 2024 EPS guidance reaffirmed.PRGO
Q2 20242 Feb 2026 - Margin expansion and innovation drive growth, with infant formula and Opill as key catalysts.PRGO
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 20242 Feb 2026 - Cost savings, infant formula rebound, and branded growth set to drive EPS above $3 in 2025.PRGO
Oppenheimer’s 24th Annual Consumer Growth & E-Commerce Conference1 Feb 2026 - Branded growth, cost savings, innovation, and debt optimization drive margin and EPS outlook.PRGO
Piper Sandler Growth Frontiers Conference21 Jan 2026 - Three-year plan targets growth, margin expansion, and higher free cash flow via brand and operational focus.PRGO
UBS Global Consumer and Retail Conference26 Dec 2025